Lineage Cell Therapeutics (LCTX) Cash from Operations (2010 - 2026)

Lineage Cell Therapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 8078000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 65.33% year-over-year to 8078000.0 in Q1 2026; TTM through Mar 2026 was 22111000.0, a 0.38% change from a year earlier, with the FY2025 full-year figure at 18919000.0, up 18.07% from the prior year.
• Cash from Operations fell to 8078000.0 in Q1 2026 per LCTX's latest filing, from 4878000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 21904000.0 in Q1 2022 and bottomed at 11242000.0 in Q1 2023.
• The 5-year median for Cash from Operations is 5783000.0 (2024), against an average of 4564470.59.
• Across the five-year window, Cash from Operations soared 395.04% in 2022 and slumped 151.32% in 2023, its largest moves.
• Year by year, Cash from Operations stood at 8303000.0 in 2022, then climbed by 27.51% to 6019000.0 in 2023, then slipped by 5.43% to 6346000.0 in 2024, then climbed by 23.13% to 4878000.0 in 2025, then slumped by 65.6% to 8078000.0 in 2026.
• Per Business Quant, the three latest LCTX Cash from Operations figures stand at 8078000.0 (Q1 2026), 4878000.0 (Q4 2025), and 3616000.0 (Q3 2025).